Semax peptide nasal spray represents a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH 4-10) designed for specialized intranasal administration in preclinical research models. In laboratory settings, researchers evaluate this compound for its potential impact on neurotrophic factor expression, brain-derived neurotrophic factor (BDNF) upregulation, and central nervous system stress response pathways. PX1 Research provides high-purity, laboratory-grade Semax formulations verified via lot-specific analytical documentation for qualified research applications.
Semax peptide nasal spray represents a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH 4-10) designed for specialized intranasal administration in preclinical research models. In laboratory settings, researchers evaluate this compound for its potential impact on neurotrophic factor expression, brain-derived neurotrophic factor (BDNF) upregulation, and central nervous system stress response pathways. PX1 Research provides high-purity, laboratory-grade Semax formulations verified via lot-specific analytical documentation for qualified research applications.
Semax peptide nasal spray is a specialized, liquid-buffered research formulation of the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, a synthetic derivative of the adrenocorticotropic hormone fragment ACTH(4-10) stabilized with a C-terminal Pro-Gly-Pro tripeptide. It is utilized in preclinical intranasal models to investigate neurotrophic signaling, BDNF gene expression, and cellular defense mechanisms against ischemic or oxidative stress.
Unlike standard unmodified neuropeptides that exhibit rapid enzymatic degradation in plasma, the structural modification of Semax significantly prolongs its biological half-life in extracellular environments. Researchers examining central nervous system (CNS) dynamics frequently employ nasal spray delivery systems in animal models to bypass the blood-brain barrier via olfactory and trigeminal nerve pathways. This intranasal research methodology allows for precise assessment of central peptide activity without requiring invasive stereotaxic intraparenchymal microinjections.
The primary structure of Semax consists of seven amino acids: H-Met-Glu-His-Phe-Pro-Gly-Pro-OH. The base sequence Met-Glu-His-Phe represents the ACTH(4-7) core fragment responsible for target receptor engagement, while the terminal Pro-Gly-Pro tripeptide sequence protects the molecule against endogenous carboxypeptidases and aminopeptidases. This structural extension drastically enhances peptide stability in rodent plasma assays compared to native ACTH fragments.
In chemical synthesis, maintaining exact sequence fidelity and stereochemical purity is vital. Imidazolic side chains on histidine and thioether groups on methionine present specific susceptibility to oxidation under ambient laboratory conditions. Standardized formulations of Semax peptide nasal spray rely on exact pH buffer solutions—typically mild phosphate or saline buffers maintained between pH 6.0 and 7.0—to preserve structural integrity, prevent aggregation, and eliminate non-enzymatic degradation during long-term experimental protocols.
The principal mechanism investigated in preclinical studies involving Semax centers on the modulation of neurotrophic factors, primarily Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF). In rodent models, acute intranasal administration of Semax has been shown to induce a rapid upregulation of BDNF mRNA expression in the hippocampus and frontal cortex. This transcriptional response is accompanied by a concurrent increase in tropomyosin receptor kinase B (TrkB) receptor phosphorylation.
Through downstream TrkB receptor activation, researchers monitor intracellular signaling cascades including the MAPK/ERK and PI3K/Akt pathways. Preclinical assays indicate that these pathways regulate synaptic plasticity, dendritic spine density, and long-term potentiation (LTP) in hippocampal slice preparations. Furthermore, in vitro studies using primary neuronal cultures demonstrate that exposure to Semax alters transcriptional profiling related to neurotransmitter biosynthesis and receptor subunit assembly, particularly within glutamatergic and dopaminergic systems.
Beyond neurotrophic signaling, Semax is heavily studied in cellular models of hypoxia, focal cerebral ischemia, and metabolic stress. In rodent middle cerebral artery occlusion (MCAO) models, preclinical data demonstrate that Semax administration reduces the activation of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), while suppressing inducible nitric oxide synthase (iNOS) expression.
Additionally, transcriptomic analysis of ischemic brain tissue treated with Semax reveals significant changes in the expression of genes governing vascular tone, extracellular matrix remodeling, and apoptotic cascades. Preclinical studies suggest that Semax modulates the expression of vascular endothelial growth factor (VEGF) and its associated receptor VEGFR2, offering a mechanistic lens for investigating local angiogenesis and microvascular survival under conditions of reduced oxygenation. Researchers analyzing neuroprotective peptide mechanisms utilize these baseline parameters to assess tissue recovery markers.
Within the category of synthetic regulatory peptides studied for central nervous system modulation, Semax is often evaluated alongside other neuropeptides such as Selank and candidate neurotrophic fragments like P21. While both Semax and Selank incorporate the stabilizing Pro-Gly-Pro sequence at their C-terminus, their N-terminal structures and primary biological pathways diverge significantly.
Semax derives from ACTH(4-10) and predominantly drives neurotrophic signaling via BDNF upregulation, making it a focus for cognitive, ischemic, and neuroplasticity assays. Conversely, Selank peptide research focuses on its derivation from the human immunomodulatory peptide Tuftsin, targeting enkephalin degradation pathways and GABAergic modulation. Meanwhile, novel mimetic compounds like P21 target CNTF receptor pathways directly. Evaluating these distinct candidate molecules within our all peptides catalog allows researchers to select appropriate positive controls or comparative compounds for multi-target neurological screens.
When designing laboratory protocols, researchers must select between pre-formulated intranasal solutions and standard lyophilized peptide vials. A pre-formulated Semax peptide nasal spray provides a precise volumetric delivery system calibrated to deliver consistent micro-droplet volumes (typically 100 µL per metered actuation) directly into nasal cavities of larger research models.
Alternatively, dry lyophilized research peptides offer extended shelf stability prior to reconstituted solution preparation. While lyophilized formats allow custom concentration adjustments and reconstitution in specialized buffers, ready-to-use liquid nasal formulations eliminate reconstitution errors and reduce handling steps in high-throughput animal trials. Both formats require strict storage temperature controls to avoid chemical hydrolysis or thermal denaturation.
To maintain analytical consistency, proper laboratory handling procedures are mandatory. Liquid intranasal formulations of Semax should be maintained at refrigerated temperatures (2°C to 8°C) immediately upon receipt. Unopened liquid solutions must be protected from prolonged exposure to light and kept in vertical orientation to protect the integrity of the metered pump mechanism.
If working with dry powder formats intended for nasal application, reconstitution should be performed using sterile, preservative-free normal saline (0.9% NaCl) or a designated phosphate-buffered saline (PBS) solution adjusted to pH 6.4. Reconstitution using unbuffered sterile water can alter osmotic pressure, resulting in variable mucosal absorption rates in rodent models. Once reconstituted, solution aliquots should be used within defined experimental windows to avoid peptide oxidation.
Assaying peptide validity requires robust analytical metrics. High-performance liquid chromatography (HPLC) paired with mass spectrometry (MS) provides unambiguous verification of molecular weight, sequence identity, and chemical purity. Research institutions must demand lot-specific Certificates of Analysis (COA) to confirm that purity thresholds meet or exceed 98.0%.
Key analytical metrics for laboratory-grade Semax include:
- **Purity by RP-HPLC:** Single prominent peak confirming minimal peptide degradation or truncated synthesis fragments. - **Mass Spectrometry Identification:** Exact theoretical mass match (810.9 g/mol for the free base) to confirm correct amino acid assembly. - **Endotoxin Quantification:** Limulus Amebocyte Lysate (LAL) testing ensuring bacterial endotoxin levels remain below strictly defined laboratory limits (<0.01 EU/µg). - **Trifluroacetate (TFA) Residual Content:** Quantitative analysis of residual salt counterions to prevent artifactual cellular toxicity in delicate primary neuron assays.
Reliability and batch-to-batch consistency are critical when acquiring research compounds for longitudinal studies. PX1 Research manufactures and tests Semax formulations exclusively within USA-based, ISO 17025 accredited, and GMP-compliant laboratories. Every lot undergoes rigorous third-party analytical testing prior to release, guaranteeing full traceability and exact chemical specifications.
Whether procuring individual reference standards or establishing a bulk laboratory supply via our wholesale lab account portal, researchers receive fully documented compounds with batch-matched COAs. PX1 Research facilitates seamless experimental workflows with same-day shipping options from California and Arizona facility hubs.
What is the theoretical molecular weight and sequence of Semax?
Semax is a heptapeptide with the chemical sequence Met-Glu-His-Phe-Pro-Gly-Pro and a theoretical molecular weight of approximately 810.9 g/mol. It is a synthetic derivative of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro stabilization extension.
How should Semax peptide nasal spray be stored upon arrival?
Liquid Semax nasal spray formulations must be stored under refrigeration at 2°C to 8°C. Protect the solution from direct light exposure and avoid freeze-thaw cycles, which can cause aggregation or peptide chain cleavage.
What purity level is required for in vitro and preclinical research?
Preclinical cellular and animal research generally requires a minimum purity of 98.0% verified via Reversed-Phase HPLC. PX1 Research provides lot-specific COAs confirming both chromatographic purity and mass spectrometry identity.
Why is Semax studied via intranasal administration in animal models?
Intranasal administration allows neuropeptides to pass along olfactory and trigeminal nerve pathways directly to the central nervous system, bypassing the blood-brain barrier and avoiding systemic hepatic metabolism.
What is the primary difference between Semax and Selank in research literature?
Semax is an ACTH(4-10) analog primarily studied for neurotrophic factor expression (BDNF/NGF) and ischemic stress response. Selank is a Tuftsin analog predominantly evaluated for its effects on enkephalin pathways and GABAergic signaling.
How are endotoxin levels tested for PX1 Research compounds?
PX1 Research utilizes standardized Limulus Amebocyte Lysate (LAL) assays to quantify endotoxin presence. Lot-specific COAs document that endotoxin levels remain below strict threshold limits suitable for sensitive laboratory applications.
Is Semax peptide nasal spray intended for human consumption or therapeutic use?
No. All compounds supplied by PX1 Research, including Semax peptide nasal spray, are strictly intended for in vitro and preclinical laboratory research use only. They are not for human or veterinary medical use, therapy, or consumption.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.